Affordable Access

Publisher Website

A Nomogram for Identifying HR+/Her2− Breast Cancer Patients with Positive Sentinel Lymph Nodes and Omitted Axillary Lymph Node Dissection Who Need Abemaciclib Therapy

Authors
  • Yang, Hanzhao
  • Sun, Yadong
  • Wang, Peili
  • Qiao, Jianghua
  • Li, Lianfang
  • Lu, Zhenduo
  • Sun, Xianfu
  • Zhang, Chongjian
  • Chen, Xiuchun
  • Yan, Min
  • Cui, Shude
  • Wang, Chengzheng
  • Liu, Zhenzhen
Type
Published Article
Journal
Medical Science Monitor
Publisher
"International Scientific Information, Inc."
Publication Date
Jul 16, 2023
Volume
29
Identifiers
DOI: 10.12659/MSM.940124
PMID: 37454245
PMCID: PMC10357967
Source
PubMed Central
Keywords
Disciplines
  • Clinical Research
License
Unknown

Abstract

Background The efficacy of abemaciclib in high-risk patients with early-stage HR+/Her2− breast cancer has been verified by MonarchE. However, accurately determining the number of axillary lymph node (ALN) metastases remains challenging. The Z0011 trial changed the axillary management strategy, eliminating the need for axillary lymph node dissection (ALND) in patients with 1–2 sentinel lymph node (SLN) metastases. Therefore, further exploration is needed to identify patients who could benefit from abemaciclib therapy. Material/Methods This retrospective study included cT1-2N0M0 HR+/Her2− patients with 1–2 positive SLNs who underwent ALND. Clinicopathological data were collected, and logistic regression analyses identified independent predictors for ≥4 positive ALNs. A predictive nomogram was developed, and discrimination and calibration were evaluated using the C-index and calibration curve. Clinical efficacy was assessed using decision curve analysis (DCA). Results We enrolled 444 patients, with 77 (17.3%) having ≥4 positive ALNs. Independent predictors for ≥4 positive ALNs included abnormal ALN on ultrasound, mammographic calcifications, T stage, and the number of positive SLNs. The nomogram demonstrated an AUC of 0.777 (95% CI: 0.735–0.815, P <0.001), and internal validation showed good calibration and discrimination (C-index, 0.802; 95% CI: 0.779–0.824). DCA revealed a positive net benefit for risk levels ranging from 5% to 54%. Conclusions This nomogram is a convenient and reliable tool to predict the risk of ≥4 positive ALNs in HR+/Her2− patients. It aids in protocol selection by identifying SLN-positive patients who may benefit from abemaciclib therapy without ALND.

Report this publication

Statistics

Seen <100 times